Emerging Markets Report: More Tools in the Toolbox

Rhea-AI Summary

Mindset Pharma (CSE: MSET, OTCQB: MSSTF) has filed a new provisional patent application expanding its next-generation DMT and 5-MeO-DMT compounds, part of the Company’s ongoing strategy to enhance treatment options for mental health disorders. This patent covers new chemical entities that strengthen their psychedelic drug development pipeline. CEO James Lanthier emphasized the importance of differentiated treatments as more data from clinical trials emerges. This move positions Mindset favorably in the growing psychedelic market, which is experiencing increasing acceptance and potential regulatory changes.

Positive

• Filed a provisional patent application for new chemical entities, enhancing the DMT and 5-MeO-DMT platform.
• Strengthens the Company’s strategy to provide innovative treatment options for mental health disorders.
• Potential market growth as societal acceptance of psychedelics continues to increase.

Negative

• None.

An Emerging Markets Sponsored Commentary

ORLANDO, Fla., April 22, 2022 (GLOBE NEWSWIRE) -- Sometimes as we continue our coverage of Mindset Pharma Inc. (Mindset) (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) it feels as if we are covering TWO unique stories.

And maybe we are.

As you may recall, Mindset is a drug discovery and development company focused on creating next-generation psychedelic medicines to treat neurological and psychiatric disorders. Most of what we cover about Mindset are the Company’s advancements in drug development that assist them in their perpetual goal of helping patients have better outcomes using psychedelics.

But perhaps the larger, parallel story is that this psychedelics-as-medicine paradigms seems to be at a point that real treatments are emerging and doctors and companies are learning from these early treatments.

This article from Harvard Health Publishing talks both about how far psychedelics have come … and how far they might go.

And this article from the venerable New York Times leads with the bold headline, “The Psychedelic Revolution is Coming. Psychiatry May Never Be the Same.”

That’s why the recent news from psychedelic pioneers Mindset Pharma is incredibly important. In the release, Mindset announces the filing of a new provisional patent application that covers new chemical entities (NCEs) that expand the Company’s next-generation DMT and 5-MeO-DMT, or ‘Family 4’, platform, currently under development.

This new patent application exemplifies the Mindset corporate strategy to broaden the therapeutic psychedelic toolbox for patients with mental health disorders who are waiting for transformative medicines and covers novel chemical space while maintaining the functionality of traditional psychedelics.

A quote from CEO James Lanthier explains the significance of the filing:

“As we get more human clinical data from first generation psychedelic drugs, we will unravel how different patients respond to different psychedelic therapies. Our expectation is that different patients will respond to different treatments and paradigms. In an effort to build a toolbox that helps the most patients, Mindset continues to build out its patent portfolio.”

And that’s the part we think is compelling, even resonant. Mindset is growing in a growth industry, developing more options as acceptance broadens and the earth moves under its proverbial feet. Remember when Washington and Colorado were rebels, bold early adopters that were the first states to legalize recreational cannabis use? Now, we’re talking about the possible end to federal prohibition as a vast amount of states allow recreational and medical use.

We may be at a similar precipice, a tipping point. Those articles from The New York Times and Harvard are from last year. Since that time Mindset has put more tools in the tool box.

And let’s not kid ourselves. Mindset is a public company and as much as the narrative is and should be about the potentially transformative effects of psychedelic treatments, the story may someday be about a Company who has generated intellectual property with potential revenue streams that could be valuable in a fully exploited psychedelic health care market.

It wasn’t that long ago that Oregon was the first to legalize psychedelic mushrooms, a move that if similar to the seminal decriminalization of cannabis in Washington and Colorado a decade ago, could lead a very large psychedelic treatment market sooner than later.

If that happens, Mindset is already well down the road of putting tools in the toolbox.

About The Emerging Markets Report:

The Emerging Markets Report is owned and operated by Emerging Markets Consulting (EMC), a syndicate of investor relations consultants representing years of experience. Our network consists of stockbrokers, investment bankers, fund managers, and institutions that actively seek opportunities in the micro and small-cap equity markets.

For more informative reports such as this, please sign up at https://emergingmarketsconsulting.com/

Must Read OTC Markets/SEC policy on stock promotion and investor protection

• https://www.otcmarkets.com/learn/policy-on-stock-promotion
• https://www.otcmarkets.com/learn/investor-protection
• https://www.sec.gov/news/press-release/2017-79
• https://www.sec.gov/oiea/investor-alerts-bulletins/ia_promotions.html

Section 17(b) of the Securities Act of 1933 requires that any person that uses the mails to publish, give publicity to, or circulate any publication or communication that describes a security in return for consideration received or to be received directly or indirectly from an issuer, underwriter, or dealer, must fully disclose the type of consideration (i.e. cash, free trading stock, restricted stock, stock options, stock warrants) and the specific amount of the consideration. In connection therewith, EMC has received the following compensation and/or has an agreement to receive in the future certain compensation, as described below.

EMC has been paid $250,000 by Mindset Pharma, Inc. for various marketing services including this report. EMC does not independently verify any of the content linked-to from this editorial. https://emergingmarketsconsulting.com/disclaimer/

Emerging Markets Consulting, LLC
Florida Office
390 North Orange Ave STE 2300
Orlando, FL 32801
E-mail: jamespainter@emergingmarketsllc.com
Web: https://emergingmarketsconsulting.com/

FAQ

What is Mindset Pharma's recent patent application about?

Mindset Pharma recently filed a provisional patent application for new chemical entities that expand their DMT and 5-MeO-DMT compounds, aimed at developing more treatment options for mental health disorders.

How does Mindset Pharma's patent filing impact MSSTF investors?

The patent filing positions Mindset Pharma strategically to capture a share of the emerging psychedelic market, which could lead to future revenue streams as treatments gain acceptance.

What are the implications of the new patent for Mindset Pharma's drug development?

The new patent enhances Mindset's drug development pipeline, potentially allowing for more effective and varied treatments for patients with neurological and psychiatric disorders.

When did Mindset Pharma announce the provisional patent filing?

Mindset Pharma announced the provisional patent filing on April 22, 2022.

What is the significance of the psychedelic treatments market for Mindset Pharma?

The psychedelic treatments market is growing as acceptance increases, positioning Mindset Pharma to leverage its innovations for substantial future growth.